AbCellera Biologics Inc. (ABCL) Balance Sheet
ABCL balance sheet, 2025
December 31, 2025 · U.S. dollars$1.36B assets = $390.0M liabilities + $966.9M equity
Both columns are drawn to the same scale: what ABCL owns equals what it owes plus shareholders’ equity. Hover a block for its value.
ABCL financial health
Descriptive bands, not a rating. Fiscal 2025.
ABCL balance sheet trends, 2018–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $21.5M2018 | $1.36B2025 | +80.8%/yr | |
| Total liabilities | $9.9M2018 | $390.0M2025 | +69.1%/yr | |
| Shareholders’ equity | $11.6M2018 | $966.9M2025 | +88.1%/yr | |
| Cash & short-term investments | $10.4M2018 | $533.8M2025 | +75.4%/yr | |
| Total debt | $3.4M2018 | $143.2M2025 | +70.3%/yr | |
| Net cash (debt) | $7.0M2018 | $390.6M2025 | +$383.6M | |
| Working capital | $8.7M2018 | $663.9M2025 | +$655.2M | |
| Book value per share | $0.082018 | $3.242025 | +70.6%/yr | |
| Debt / equity | 0.302018 | 0.152025 | −0.15 | |
| Shares outstanding | 151.0M2018 | 298.7M2025 | +10.2%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ABCL assets
ABCL liabilities and equity
ABCL debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
ABCL balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & short-term investments | $533.8M | $625.6M | $760.6M | $886.5M | $723.0M | $594.1M | $7.6M | $10.4M |
| Cash & equivalents | $128.5M | $156.3M | $133.3M | $386.5M | $476.1M | $594.1M | $7.6M | $10.4M |
| Short-term investments | $405.3M | $469.3M | $627.3M | $499.9M | $246.8M | $594.1M | — | — |
| Receivables | $153.4M | $92.1M | $64.4M | $103.4M | $174.9M | $213.7M | $2.1M | $1.4M |
| Inventory | $6.3M | $0 | $1.1M | $1.5M | $1.7M | $1.4M | $163,000 | $1 |
| Other current assets | $34.7M | $33.6M | $45.9M | $34.1M | $30.3M | $4.1M | $2.8M | $3.3M |
| Total current assets | $728.2M | $751.4M | $872.0M | $1.03B | $929.8M | $813.3M | $12.6M | $15.2M |
| Property, plant & equipment (net) | $428.0M | $340.4M | $287.7M | $217.3M | $111.6M | $17.9M | $8.5M | $6.3M |
| Goodwill & intangible assets | $86.2M | $89.9M | $168.2M | $179.3M | $196.2M | $146.7M | $0 | $0 |
| Long-term investments | $62.6M | $82.3M | $65.9M | $72.5M | $50.3M | $19.2M | $0 | $0 |
| Other non-current assets | $51.9M | $96.5M | $94.2M | $46.3M | $30.6M | $8.4M | $2.4M | $0 |
| Total assets | $1.36B | $1.36B | $1.49B | $1.54B | $1.32B | $1.01B | $23.5M | $21.5M |
| Liabilities | ||||||||
| Accounts payable | $25.2M | $34.4M | $25.5M | $14.8M | $14.9M | $7.3M | $1.6M | $1.5M |
| Short-term debt | $5.8M | $4.6M | $6.2M | $5.6M | $3.7M | $865,000 | $2.9M | $2.5M |
| Deferred revenue | $22.5M | $21.2M | $19.0M | $21.6M | $7.5M | $7.5M | $3.3M | $2.3M |
| Total current liabilities | $64.3M | $76.6M | $119.0M | $118.3M | $120.7M | $103.5M | $7.9M | $6.4M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $2.2M | $1.4M | $911,224 |
| Lease obligations | $143.2M | $65.4M | $77.4M | $82.3M | $36.4M | $3.7M | $3.1M | $0 |
| Other long-term liabilities | $325.7M | $227.9M | $216.8M | $189.3M | $172.2M | $69.3M | $4.0M | $2.5M |
| Total liabilities | $390.0M | $304.5M | $335.8M | $307.6M | $292.8M | $175.0M | $13.2M | $9.9M |
| Shareholders' equity | ||||||||
| Common stock & paid-in capital | $802.3M | $777.2M | $753.2M | $734.4M | $722.4M | $710.4M | $5.1M | $5.1M |
| Retained earnings (deficit) | −$29.5M | $116.9M | $279.8M | $426.2M | $267.7M | $114.2M | −$4.7M | −$2.5M |
| Accumulated other comprehensive income | −$4.2M | −$4.4M | −$1.7M | −$1.4M | $280,000 | $0 | $0 | −$1.6M |
| Total shareholders' equity | $966.9M | $1.06B | $1.15B | $1.23B | $1.03B | $830.5M | $10.3M | $11.6M |
| Key figures | ||||||||
| Total debt | $143.2M | $65.4M | $77.4M | $82.3M | $40.1M | $6.8M | $6.9M | $3.4M |
| Net cash (debt) | $390.6M | $560.2M | $683.2M | $804.2M | $682.9M | $587.3M | $662,000 | $7.0M |
| Working capital | $663.9M | $674.8M | $753.0M | $907.2M | $809.1M | $709.8M | $4.7M | $8.7M |
| Tangible book value | $880.7M | $966.2M | $984.1M | $1.05B | $829.5M | $683.9M | $10.3M | $11.6M |
| Book value per share | $3.24 | $3.59 | $3.98 | $3.92 | $3.22 | $3.16 | $0.04 | $0.08 |
| Shares outstanding | 298.7M | 294.3M | 289.2M | 314.8M | 318.3M | 263.1M | 237.7M | 151.0M |
| Current ratio | 11.32 | 9.81 | 7.33 | 8.67 | 7.70 | 7.86 | 1.60 | 2.36 |
| Quick ratio | 10.69 | 9.37 | 6.93 | 8.37 | 7.44 | 7.81 | 1.23 | 1.84 |
| Debt / equity | 0.15 | 0.06 | 0.07 | 0.07 | 0.04 | 0.01 | 0.67 | 0.30 |
| Equity / assets | 71.3% | 77.6% | 77.4% | 80.0% | 77.8% | 82.6% | 43.6% | 54.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $540.1M | $504.7M | $533.8M | $495.7M | $553.1M | $605.3M | $625.6M | $643.1M | $670.4M | $698.0M | $760.6M | $785.8M |
| Cash & equivalents | $120.1M | $77.1M | $128.5M | $83.2M | $92.4M | $159.3M | $156.3M | $126.6M | $148.3M | $123.6M | $133.3M | $172.4M |
| Short-term investments | $420.0M | $427.7M | $405.3M | $412.5M | $460.6M | $446.0M | $469.3M | $516.5M | $522.0M | $574.5M | $627.3M | $613.4M |
| Receivables | $95.4M | $115.7M | $153.4M | $159.4M | $153.4M | $126.6M | $92.1M | $63.2M | $67.7M | $68.8M | $64.4M | $75.5M |
| Inventory | $7.6M | $7.9M | $6.3M | $0 | $0 | $0 | $0 | $0 | $1 | $738,000 | $1.1M | $1.2M |
| Other current assets | $36.1M | $36.3M | $34.7M | $40.1M | $35.7M | $33.1M | $33.6M | $36.5M | $33.5M | $46.4M | $45.9M | $57.0M |
| Total current assets | $679.2M | $664.6M | $728.2M | $695.1M | $742.1M | $765.0M | $751.4M | $742.9M | $771.6M | $813.9M | $872.0M | $919.5M |
| Property, plant & equipment (net) | $902.9M | $422.8M | $428.0M | $427.4M | $424.0M | $347.1M | $340.4M | $331.3M | $318.9M | $306.1M | $287.7M | $277.2M |
| Goodwill & intangible assets | $84.3M | $85.3M | $86.2M | $87.1M | $88.1M | $89.0M | $89.9M | $100.4M | $133.5M | $166.5M | $168.2M | $171.9M |
| Long-term investments | $65.2M | $65.3M | $62.6M | $93.3M | $90.4M | $81.6M | $82.3M | $84.1M | $76.1M | $71.6M | $65.9M | $62.9M |
| Other non-current assets | $0 | $69.1M | $51.9M | $53.1M | $57.5M | $61.6M | $96.5M | $134.2M | $112.5M | $104.9M | $94.2M | $80.7M |
| Total assets | $1.31B | $1.31B | $1.36B | $1.36B | $1.40B | $1.34B | $1.36B | $1.39B | $1.41B | $1.46B | $1.49B | $1.51B |
| Liabilities | ||||||||||||
| Accounts payable | $12.1M | $20.8M | $25.2M | $31.8M | $32.0M | $32.8M | $34.4M | $34.8M | $26.6M | $26.9M | $28.6M | $17.4M |
| Short-term debt | $5.7M | $5.9M | $5.8M | $5.2M | $4.9M | $4.6M | $4.6M | $5.1M | $5.6M | $5.5M | $6.2M | $5.6M |
| Deferred revenue | $20.7M | $16.7M | $22.5M | $24.6M | $25.1M | $26.0M | $21.2M | $13.4M | $6.4M | $10.6M | $26.1M | $23.9M |
| Total current liabilities | $53.2M | $47.3M | $64.3M | $68.8M | $67.0M | $75.4M | $76.6M | $79.6M | $70.4M | $104.9M | $119.0M | $110.2M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $135.6M | $140.2M | $143.2M | $142.2M | $142.1M | $67.8M | $65.4M | $71.4M | $72.1M | $73.6M | $77.4M | $80.8M |
| Other long-term liabilities | $358.4M | $321.7M | $325.7M | $323.1M | $328.0M | $245.8M | $227.9M | $235.2M | $231.1M | $228.3M | $216.8M | $219.2M |
| Total liabilities | $411.6M | $369.0M | $390.0M | $392.0M | $395.0M | $321.2M | $304.5M | $314.7M | $301.5M | $333.2M | $335.8M | $329.4M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $821.2M | $816.5M | $802.3M | $794.5M | $791.7M | $790.1M | $777.2M | $772.8M | $770.0M | $764.6M | $753.2M | $747.9M |
| Retained earnings (deficit) | −$128.1M | −$72.6M | −$29.5M | −$20.5M | $36.6M | $71.3M | $116.9M | $151.1M | $202.2M | $239.2M | $279.8M | $326.9M |
| Accumulated other comprehensive income | −$3.2M | −$2.4M | −$4.2M | −$2.7M | −$2.7M | −$7.0M | −$4.4M | −$1.2M | −$2.1M | −$1.8M | −$1.7M | −$1.5M |
| Total shareholders' equity | $896.0M | $938.1M | $966.9M | $964.0M | $1.01B | $1.02B | $1.06B | $1.08B | $1.11B | $1.13B | $1.15B | $1.18B |
| Key figures | ||||||||||||
| Total debt | $135.6M | $140.2M | $143.2M | $142.2M | $142.1M | $67.8M | $65.4M | $71.4M | $72.1M | $73.6M | $77.4M | $80.8M |
| Net cash (debt) | $404.5M | $364.6M | $390.6M | $353.5M | $411.0M | $537.4M | $560.2M | $571.7M | $598.3M | $624.4M | $683.2M | $705.1M |
| Working capital | $626.0M | $617.3M | $663.9M | $626.3M | $675.1M | $689.6M | $674.8M | $663.3M | $701.2M | $709.1M | $753.0M | $809.3M |
| Tangible book value | $811.7M | $852.8M | $880.7M | $876.9M | $919.0M | $934.0M | $966.2M | $977.7M | $977.5M | $963.4M | $984.1M | $1.01B |
| Book value per share | $2.93 | $3.10 | $3.24 | $3.23 | $3.37 | $3.44 | $3.58 | $3.66 | $3.78 | $3.86 | $3.96 | $4.09 |
| Shares outstanding | 305.6M | 303.1M | 298.7M | 298.9M | 298.5M | 297.7M | 294.6M | 294.9M | 294.2M | 292.7M | 290.9M | 289.5M |
| Current ratio | 12.77 | 14.05 | 11.32 | 10.10 | 11.07 | 10.15 | 9.81 | 9.34 | 10.96 | 7.76 | 7.33 | 8.34 |
| Quick ratio | 11.95 | 13.12 | 10.69 | 9.52 | 10.54 | 9.71 | 9.37 | 8.88 | 10.49 | 7.31 | 6.93 | 7.81 |
| Debt / equity | 0.15 | 0.15 | 0.15 | 0.15 | 0.14 | 0.07 | 0.06 | 0.07 | 0.06 | 0.07 | 0.07 | 0.07 |
| Equity / assets | 68.5% | 71.8% | 71.3% | 71.1% | 71.8% | 76.1% | 77.6% | 77.4% | 78.7% | 77.2% | 77.4% | 78.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 24, 2026); data from EODHD.
ABCL financial position
At the end of fiscal 2025 (December 31, 2025), AbCellera Biologics had total assets of $1.4 billion (down 0.3% from a year earlier), total liabilities of $390.0 million and shareholders' equity of $966.9 million. It held $533.8 million in cash and short-term investments against $143.2 million of debt, a net cash position of $390.6 million. Its current ratio was 11.32. In the latest quarter (ended June 30, 2026) total assets were $1.3 billion and equity $896.0 million.
Related: ABCL income statement, ABCL cash flow statement, ABCL key metrics. See the ABCL stock overview for the latest quote and news.
ABCL balance sheet FAQ
What are AbCellera Biologics's total assets?
AbCellera Biologics reported total assets of $1.4 billion at the end of fiscal 2025 (December 31, 2025), compared with $1.4 billion a year earlier.
How much debt does AbCellera Biologics have?
AbCellera Biologics had $143.2 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.15.
How much cash does AbCellera Biologics have?
AbCellera Biologics held $533.8 million in cash and short-term investments at the end of fiscal 2025; with $143.2 million of debt that is net cash of $390.6 million.
What is AbCellera Biologics's book value?
AbCellera Biologics's shareholders' equity (book value) was $966.9 million at the end of fiscal 2025, or $3.24 per share.
What is AbCellera Biologics's current ratio?
AbCellera Biologics had current assets of $728.2 million and current liabilities of $64.3 million, a current ratio of 11.32 (it can cover its short-term obligations).
How much goodwill does AbCellera Biologics have?
AbCellera Biologics carried $86.2 million of goodwill and intangible assets, 6.4% of total assets, at the end of fiscal 2025.